Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Healthcare Drug Manufacturers - Major Cannabis
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Aphria Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Sasha.Nikon Jan 11, 2019 1:43pm
60 Views
Post# 29219826

RE:RE:RE:RE:Uncertainty

RE:RE:RE:RE:Uncertainty
skyplt wrote: Exactly...a market would not exist if it were not for differing views.

Pragmatically, I see the chances of going back to 8 verses risking missing a bump to the low teens should an offer arise, as favouring a hold strategy.  

But that did not work out so well for me last Nov/Dec.

One of us will be right.  Best of luck (sincerely)

Sasha.Nik wrote:
skyplt wrote: Completely disagree with you on this.  Today was all about clearing the way for another suitor (or two or three) to take a run at Aphria.

Everyone agrees Aphria will be producing vast quantities...and there are truly some shell companies out there (Tilray for example) that have solid branding but no product.

This company is worth at least 16 in terms of potential...and those in the know see that.  

Today's financials were not a miss...the low end of expectations.  The focus is on 2019 and beyond.

That's what this is about.  

Sasha.Nik wrote: Tha's what's happening. Revenue missed (by huge margin). Vic and Cole leaving. Times like this ppl. rather sit out and not risk huge capital until there is more clarity. Problem is there are die hard fans of APH out there pumping this thing no matter what.

I'm gonna sit out to see how this clears up. I personally thinking a drop back under $8 in the short term. All the good was already priced into this before today. "it's sell the news" thing right now.

 


Sure, we have our own opinions, that's what makes a market. Long term you are correct. Short term though, I think we'll see some weakness.
 




You too - fyi - I'm currently long though as well - just stating my views, I hope I'm wrong and we go up. 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities